Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21915824 | 1.00 | CYP2C19 (0.54) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL1721615 | 1.00 | CYP2C19 (0.54) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL29781191 | 0.93 | CYP3A4 (0.58) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL304701 | 0.93 | CYP3A4 (0.58) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL24707932 | 0.93 | CYP3A4 (0.58) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL8028321 | 0.92 | CYP3A4 (0.57) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL3525474 | 0.92 | CYP3A4 (0.57) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL15751346 | 0.91 | KMT2A (0.51) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL6594948 | 0.89 | CYP3A4 (0.48) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 | |
| SCHEMBL25542113 | 0.87 | CYP2C19 (0.44) | CYP2C19CYP3A4CYP2C9SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098440-A1 | BISPECIFIC ANTIBODY CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| CN-115103691-B | Pharmaceutical composition containing antibody drug conjugate and application thereof | 苏州盛迪亚生物医药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119185572-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-118903456-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118806924-A | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-112512591-B | Ligand-drug conjugate of irinotecan analogue, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-113797354-B | Pyrrolopyrimidine derivatives or conjugates thereof, preparation method and application thereof | 江苏恒瑞医药股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2023116861-A1 | ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING ANTI-DLL3 ANTIBODY | 江苏恒瑞医药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4130045-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| EP-4129345-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-115103691-A | Pharmaceutical composition containing antibody drug conjugate and application thereof | 江苏恒瑞医药股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115103858-A | Preparation method of antibody drug conjugate | 江苏恒瑞医药股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | CFD, DDOST, HEXD | CYP2C19 459/4885CYP3A4 1700/4885CYP2C9 648/4885 |
| US-12617867-B2 | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | EGFR, CCKAR, MET | CYP2C19 2968/4885CYP3A4 2066/4885CYP2C9 2208/4885 |
| US-20210353764-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | GLP1R, ADGRF1, CCKAR | CYP2C19 1050/4885CYP3A4 607/4885CYP2C9 1082/4885 |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | FCGR1A, FCGR3B, FCGR2A | CYP2C19 1732/4885CYP3A4 1255/4885CYP2C9 1198/4885 |
| US-20230144203-A1 | DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | ERLIN1, ERLIN2, EZR | CYP2C19 468/4885CYP3A4 146/4885CYP2C9 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.